VEGFA and neoplasm: A single intramuscular injection of rAVV-mediated delivery of K5, a potent angiogenic inhibitor, inhibited VEGF and tumour cell-induced angiogenesis in subcutaneous and intraperitoneal human OC cells in mouse models, conferring survival advantage without toxicity.